Chemocentryx, Inc.

Arcus Biosciences, Inc.

Other

Manmohan Reddy Leleti

Jay Patrick Powers

Ju Yang

Jaroslaw Kalisiak

Yandong Li

Penglie Zhang

Venkat Reddy Mali

Hiroko Tanaka

Brandon Reid Rosen

Kenneth Victor Lawson

Dillon Harding Miles

Dean R Dragoli

Junfa Fan

Erick Allen Lindsey

Viengkham Malathong

Christopher W Lange

Xi Chen

Chao Yu

Joel Worley Beatty

Jeffrey P McMahon

Jenna Leigh Jeffrey

Ehesan Ul Sharif

Pingchen Fan

Rajinder Paul Singh

Yibin Zeng

Rebecca M Lui

Debashis Mandal

Eric Newcomb

Sreenivas Punna

Trevor T Charvat

Kevin Lloyd Greenman

Laurent Pierre Paul Debien

Samuel Lawrie Drew

Guillaume Mata

Juan Carlos Jaen

Antoni Krasinski

Andrew M K Pennell

Xuelei Yan

Rhiannon Thomas-Tran

Balint Gal

Artur Karenovich Mailyan

Anh Thu Tran

Clayton Hardman

Steven Donald Jacob

Zhang Wang

Kai Yu

Matthew Epplin

Wei Yu Chen

Daniel J Dairaghi

Yuan Xu

Lianfa Li

Yongli Su

John J Kim Wright

Tezcan Guney

Matthew J Walters

Joanne Tan

Hyunyoung Moon

Jeremy Thomas Andre Fournier

Karl T Haelsig

Ehesan Ui Sharif

Jeremy Fournier

Laurent Debien

William L Thomas

Solomon Ungashe

Mark M Gleason

Corinne Nicole Foley

Jeffrey P McMAHON

Rebecca Louise Grange

Hiufung Chu

Timothy J Sullivan

Srinivas Paladugu

Wei Chen

Andrew M Pennell

Kwok Yau

Joyson J Karakunnel

Kenken Luong

Shiwei Qu

Masa Podunavac

Dongdong Liu

Lixia Jin

Ehesan U I Sharif

Manjunath Lamani

Karen Yir Jing Chen

Pradeep Nareddy

Monika Yadav

Srijita Bhowmik

Jiang Zhu

Jeffrey Mcmahon

Jarek Kalisiak

Jeffrey P MacMahon

Jeffrey P Mcmahon

Laurent Pierre Debien

Yangdong Li

Hiroko Tankaka

John J Wright

Compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, that are mediated by 5′-nucleotidase, ecto is also provided.

Modulators of 5'-nucleotidase, ecto and the use thereof

Methods of identifying compounds that modulate the conversion of AMP to adenosine by 5'-nucleotidase, ecto, and that possess particular pharmacokinetic characteristics are described herein. Methods of such compounds, and compositions comprising same, for the treatment and/or prevention of a diverse array of diseases, disorders and conditions, including cancer- and immune-related disorders, are also provided.

Parenterally administered immune enhancing drugs

Compounds that inhibit PI3Kγ, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by PI3Kγ.

2,3,5-trisubstituted pyrazolo[1,5-A]pyrimidine compounds

The present disclosure is directed to compounds having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Thiazole compounds and methods of use thereof

Compounds that are inhibitors of at least one of ARG1 and ARG2, and compositions containing the compounds and methods for synthesizing the compounds, are described herein. The use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by ARG1 and ARG2 are also described herein.

Inhibitors of ARG1 and/or ARG2

Compound that is an inhibitor of at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. The use of such compound and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Azolopyrimidine for the treatment of cancer-related disorders

Compounds of Formula I that inhibit AXL, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer, that are mediated, at least in part, by AXL.

Compounds as inhibitors of AXL

Inhibitors of adenosine 5'-nucleotidase

The present disclosure describes processes and intermediates useful for preparing a compound of Formula (Xa) or Formula (Xb). The processes and intermediates can be used to prepare the compounds of the disclosure at multigram or kilogram scale.

Process for preparing tetralin compounds

Oxindole compounds useful for the treatment of CCR(9) mediated conditions or diseases are provided.

2-oxindole compounds

Compounds that inhibit HIF-2α, and compositions containing the compound(s) and methods for synthesizing the compounds, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by HIF-2α.

Tetralin and tetrahydroquinoline compounds as inhibitors of HIF-2alpha

The present disclosure is directed to compounds that are inhibitors of HIF-2α having a structure according to Formula I, and compositions containing those compounds. Methods of using the compounds for the treatment of diseases, disorders, or conditions are also described.

Inhibitors of HIF-2α and methods of use thereof

Compound that inhibit at least one of the Aand Aadenosine receptors, and compositions containing the compound and methods for synthesizing the compound, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine Areceptor and/or the adenosine Areceptor.

Pyridone A2R antagonists

The present invention provides solid forms, solvates and hydrates of 3-[2-amino-6-(1-{[6-(2-hydroxypropan-2-yl)pyridin-2-yl]methyl}-1H-1,2,3-triazol-4-yl)pyrimidin-4-yl]-2-methylbenzonitrile (Compound I),

Solid forms of an azolopyrimidine compound

The present disclosure provides solid solution capsule formulations of Compound 1 and methods of making the same. Also provided herein are methods of treating individuals suffering from or susceptible to a disease or disorder involving pathologic activation of C5a receptors by administering an effective amount of one or more solid solution capsules comprising Compound 1. Further provided herein are singe unit dosage capsules comprising certain amounts of Compound 1, and kits comprising a solid solution capsule comprising Compound 1.

Capsule formulations

Growing community of inventors

Dublin, CA, United States of America

Manmohan Reddy Leleti